أعرض في EDS

Recurrence risk of venous thromboembolism associated with systemic lupus erythematosus

التفاصيل البيبلوغرافية
العنوان: Recurrence risk of venous thromboembolism associated with systemic lupus erythematosus
المؤلفون: Soerajja Bhoelan, Jaime Borjas Howard, Vladimir Tichelaar, Paul van Daele, Liesbeth Hak, Alexandre Voskuyl, Maarten Limper, Robbert Goekoop, Onno Teng, Jelle Vosters, Marc Bijl, Els Zirkzee, Annemarie Schilder, Hein Bernelot Moens, Karina de Leeuw, Karina Meijer
المساهمون: Immunology, Internal Medicine, Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Rheumatology, AII - Inflammatory diseases
المصدر: Bhoelan, S, Borjas Howard, J, Tichelaar, V, van Daele, P, Hak, L, Voskuyl, A, Limper, M, Goekoop, R, Teng, O, Vosters, J, Bijl, M, Zirkzee, E, Schilder, A, Bernelot Moens, H, de Leeuw, K & Meijer, K 2022, ' Recurrence risk of venous thromboembolism associated with systemic lupus erythematosus : A retrospective cohort study ', Research and practice in thrombosis and haemostasis, vol. 6, no. 8, e12839 . https://doi.org/10.1002/rth2.12839
Research and Practice in Thrombosis and Haemostasis, 6(8):e12839. Wiley-Blackwell Publishing Ltd
Research and practice in thrombosis and haemostasis, 6(8):e12839. Wiley
Research and practice in thrombosis and haemostasis, 6(8):e12839. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis, 6(8). WILEY
سنة النشر: 2022
مصطلحات موضوعية: systemic lupus erythematosus, inflammation, venous thromboembolism, Hematology, antiphospholipid syndrome, thrombosis
الوصف: BACKGROUND: Recurrence risk of systemic lupus erythematosus (SLE)-associated venous thromboembolism (VTE) is unclear.AIM: To determine the recurrence risk of SLE-associated VTE overall and by presence of provoking factors and SLE flares.METHODS: A multicenter, retrospective cohort study was conducted among patients with first SLE-associated VTE who discontinued anticoagulation. SLE flares were defined as Systemic Lupus Erythematosus Disease Activity Index 2000 greater than 4. The primary outcome was recurrent VTE. Incidence rates and cumulative incidences were calculated by presence of provoking factors and antiphospholipid syndrome (APS) at index VTE. The hazard ratio (HR) for recurrence after SLE flare-associated index VTE was estimated with Cox regression, adjusted for provoking factor presence and APS.RESULTS: Eighty patients were included with 21 recurrent VTEs in median 8 years. For provoked index VTE, the recurrence rate in patients without APS was 1.1 per 100 person-years (PY; 95% confidence interval [CI], 0.1-3.1) and in the presence of APS 3.5 per 100 PY (95% CI, 0.9-8.9), yielding cumulative incidences of 7.5% (95% CI, 1.2%-21.7%) and 31.4% (95% CI, 6.3%-61.6%) respectively. For unprovoked index VTE, these analogous rates were 3.8 per 100 PY (95% CI, 1.2-9.0) and 16.7 per 100 PY (95% CI, 4.5-42.7), with cumulative incidences of 33.7% (95% CI, 10.7%-58.9%) and 54.2% (95% CI, 10.7%-84.5%), respectively. Forty-six index VTEs were flare associated, and the adjusted HR for recurrence was 0.4 (95% CI, 0.1-1.8) compared to those without flares at their index VTE.CONCLUSION: Antiphospholipid syndrome is the main determinant for recurrence risk of SLE-associated VTE irrespective of presence of a provoking factor. Future research should attempt to confirm that flare-associated VTE has a lower recurrence risk.
وصف الملف: application/pdf
اللغة: English
تدمد: 2475-0379
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e9eabb31f2fb0788ad7289e72de7996
https://doi.org/10.1002/rth2.12839
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....6e9eabb31f2fb0788ad7289e72de7996
قاعدة البيانات: OpenAIRE
الوصف
تدمد:24750379